Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Cullinan Oncology LLC

Healthcare US CGEM

18.15USD
0.50(2.83%)

Last update at 2026-06-25T15:42:00Z

Day Range

17.5118.63
LowHigh

52 Week Range

5.6816.74
LowHigh

Fundamentals

  • Previous Close 17.65
  • Market Cap860.68M
  • Volume225142
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-241.33699M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 18.94M
  • Diluted EPS TTM-3.36

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -219.87900M -167.45800M -169.22300M 151.32M -67.48500M
Minority interest 0.00000M 0.19M 1.94M -2.01900M -1.91500M
Net income -219.87900M -167.38300M -153.16200M 111.21M -65.04000M
Selling general administrative 54.25M 52.82M 42.49M 40.19M 29.15M
Selling and marketing expenses - 0.89M 42.14M - -
Gross profit -0.31100M -0.30600M -0.31000M - 18.94M
Reconciled depreciation 0.31M 0.31M 0.31M 0.09M 0.05M
Ebit -241.95900M -167.45800M -190.64900M 144.65M -68.00700M
Ebitda -241.64800M -167.15200M -190.33900M -408.92200M -67.95400M
Depreciation and amortization 0.31M 0.31M 0.31M -553.57000M 0.05M
Non operating income net other - - - 6.67M 0.47M
Operating income -241.64800M -196.91900M -191.08900M 144.65M -67.95400M
Other operating expenses 241.65M 196.92M 191.09M 132.14M 86.90M
Interest expense - - - -562.35000M 65.45M
Tax provision 0.00000M 0.12M -14.12200M 42.12M -
Interest income 22.21M 29.66M 21.63M 6.61M 0.48M
Net interest income 22.21M 29.66M 21.63M 6.61M 0.48M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - 0.12M -14.12200M 42.12M -2.44500M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 18.94M
Total operating expenses 241.65M 196.61M 191.09M 132.14M 86.90M
Cost of revenue 0.31M 0.31M 0.31M - -
Total other income expense net 21.77M 29.46M 21.87M 6.67M 0.47M
Discontinued operations - - - - -
Net income from continuing ops -219.87900M -167.57500M -155.10100M 109.19M -65.57000M
Net income applicable to common shares - - - 111.21M -65.57000M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 448.37M 621.82M 485.10M 561.12M 437.19M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 8.86M 12.69M 13.12M 7.18M 6.10M
Total liab 39.64M 31.50M 31.20M 26.09M 11.81M
Total stockholder equity 408.73M 590.33M 453.70M 535.03M 422.58M
Deferred long term liab - - - - 0.07M
Other current liab 36.12M 27.66M 24.20M 18.24M 8.58M
Common stock 0.00600M 0.00600M 0.00400M 0.00500M 0.00400M
Capital stock 0.00600M 0.00600M 0.00400M 0.00500M 0.00400M
Retained earnings -588.11900M -368.24000M -200.85700M -47.69500M -158.90900M
Other liab - - - - 0.07M
Good will - - - - -
Other assets - - 0.00000M 0.46M 6.32M
Cash 88.33M 83.00M 98.43M 550.12M 430.86M
Cash and equivalents - - - - -
Total current liabilities 37.74M 30.65M 28.14M 22.50M 11.75M
Current deferred revenue - - - - -
Net debt -85.64900M -80.85400M -94.84400M -544.92900M -430.86300M
Short term debt 0.78M 1.30M 1.44M 1.60M -
Short long term debt - - - 0.18M -
Short long term debt total 2.68M 2.15M 3.59M 5.19M -
Other stockholder equity 995.82M 958.70M 654.68M 585.32M 582.32M
Property plant equipment - - - 1.17M 0.08M
Total current assets 386.76M 414.67M 480.19M 474.47M 296.56M
Long term investments 58.27M 204.44M 0.00000M 80.88M 140.40M
Net tangible assets - - - 535.03M 424.97M
Short term investments 289.56M 315.97M 368.63M 311.14M 230.69M
Net receivables - 3.00M 5.40M - -
Long term debt - - - - -
Inventory - - -5.40000M - -
Accounts payable 0.84M 1.68M 2.49M 2.66M 3.17M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - 0.40M
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 1.02M -0.13300M -0.12900M -2.60100M -0.83800M
Additional paid in capital - - - - -
Common stock total equity - - - 0.00500M 0.00400M
Preferred stock total equity - - - - -
Retained earnings total equity - - - -47.69500M -158.90900M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.30M 0.37M 0.46M 0.46M 0.15M
Deferred long term asset charges - - - - -
Non current assets total 61.62M 207.16M 4.91M 86.64M 140.62M
Capital lease obligations 2.68M 2.15M 3.59M 5.01M -
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 180.04M -136.31400M 35.81M -24.98300M -333.77500M
Change to liabilities - - - 12.31M -0.27200M
Total cashflows from investing activities 179.99M -136.31400M 35.81M 248.97M -333.77500M
Net borrowings - 0.00000M 1.82M -2.20000M 0.17M
Total cash from financing activities 1.09M 266.19M 40.75M -25.93300M 268.78M
Change to operating activities - - - 7.40M 1.29M
Net income -219.87900M -167.57500M -153.16200M 109.19M -67.48500M
Change in cash 5.33M -15.42900M -57.71800M 96.38M -108.42400M
Begin period cash flow 83.00M 98.43M 156.15M 59.77M 168.20M
End period cash flow 88.33M 83.00M 98.43M 156.15M 59.77M
Total cash from operating activities -175.75000M -145.30300M -134.27500M -126.66400M -43.43300M
Issuance of capital stock 0.00000M 262.65M 38.39M 0.00000M 267.27M
Depreciation 0.31M 0.31M 0.31M 0.09M 0.05M
Other cashflows from investing activities - - 0.04M 275.09M -
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - - - - -
Sale purchase of stock - - - -23.73300M 271.47M
Other cashflows from financing activities 1.09M 3.54M 0.54M -23.73902M 1.52M
Change to netincome - - - 27.99M 24.38M
Capital expenditures 0.05M 0.00000M 0.21M 1.13M 1.13M
Change receivables - - - - -
Cash flows other operating - - - -276.24700M -0.10400M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - 96.38M -108.42400M
Change in working capital 14.08M -0.38900M -0.33900M 11.18M -3.54100M
Stock based compensation 36.04M 37.82M 30.44M 27.96M 24.38M
Other non cash items -6.30600M -15.46900M -11.52200M -275.08500M 0.07M
Free cash flow -175.79900M -145.30300M -134.48300M -127.79700M -43.43300M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
CGEM
Cullinan Oncology LLC		 0.50 2.83% 18.15 - 6.74 25.86 2.11 11.55 -1.4566
NVO
Novo Nordisk A/S		 0.35 0.74% 47.76 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 0.01 0.02% 47.80 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 7.95 1.67% 483.15 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 2.83 0.45% 626.26 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in patients with relapsed and refractory acute myeloid leukemia or myelodysplastic syndrome. The company is also developing Zipalertinib, an orally available small-molecule, irreversible epidermal growth factor receptor inhibitor in Phase 2b portion of the REZILIENT1 clinical trial in patients with EGFR ex20ins non-small cell lung cancer. It has a license agreement with Chongqing Genrix Biopharmaceutical Co., Ltd to develop and commercialize velinotamig; a co-development agreement with Taiho Pharmaceutical Co., Ltd to develop zipalertinib; and a collaboration agreement with Adimab, LLC to discover and/or optimize antibodies. The company was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Cullinan Oncology LLC

One Main Street, Cambridge, MA, United States, 02142

Key Executives

Name Title Year Born
Mr. Nadim Ahmed Pres, CEO & Director 1968
Mr. Jeffrey Trigilio CFO & Treasurer 1985
Dr. Patrick A. Baeuerle Ph.D. Chief Scientific Officer 1958
Ms. Jacquelyn L. Sumer J.D. Chief Legal Officer, Chief Compliance Officer & Corp. Sec. 1978
Ms. Rose Weldon VP of Communications NA
Mr. Steve Andre Chief HR Officer NA
Dr. Corinne Savill Ph.D. Chief Bus. Officer 1959
Dr. Jennifer Michaelson Ph.D. Chief Devel. Officer 1968
Ms. Kerry Whalen Sr. Director of Preclinical & Early Devel. NA
Dr. Jeffrey Jones M.B.A., M.D., M.P.H. Chief Medical Officer 1971

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions